Development of EFTX-001 to target KRAS mutations in cancer

开发 EFTX-001 以靶向癌症中的 KRAS 突变

• 批准号: 9906510
• 负责人: Chad V Pecot
• 金额: $ 22.5万
• 依托单位: ENFUEGO THERAPEUTICS INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9906510
• 关键词: Accounting; Address; Adult; Biological Assay; Bone Marrow; Cancer Etiology; Cancer Model; Cell Line; Cell Survival; Cessation of life; Clinical Trials; Codon Nucleotides; Collaborations; Colon; Colon Carcinoma; Development; Dose; Dose-Limiting; Europe; FDA approved; Formulation; Genes; Goals; Hepatocyte; In Vitro; International; KRAS2 gene; Kidney; Lead; Legal patent; Licensing; Liver; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Messenger RNA; Missense Mutation; Mitogen-Activated Protein Kinases; Modeling; Molecular Abnormality; Mus; Mutate; Mutation; Neoplasm Metastasis; Oncogenes; Oncology; Pharmaceutical Preparations; Phase; Proto-Oncogenes; RNA Interference; RNA delivery; Research; Signal Transduction; Small Business Innovation Research Grant; System; Technology; Testing; Therapeutic; Therapeutic Index; Thermodynamics; Tissues; Toxic effect; Treatment Efficacy; Universities; Work; base; clinically relevant; efficacy study; experimental study; first-in-human; human disease; in vivo; in vivo Model; in vivo evaluation; inhibitor/antagonist; kidney cell; kinase inhibitor; lead candidate; lipid nanoparticle; mutant; nanoparticle delivery; precision drugs; precision medicine; success; systemic toxicity; tumor; tumor progression

Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other molecular aberrations, the lack of such success in mutant KRAS-driven cancers has led KRAS itself being widely regarded as “undruggable”. Although there are G12C inhibitors currently being developed, these therapies are limited to only one KRAS mutation, accounting for only ~12% of KRAS mutations, and therefore limited in therapeutic scope. We have established a C Corporation, EnFuego Therapeutics, Inc. to address the growing number of “undruggable” targets in cancer by using RNA interference (RNAi)-based therapeutics. RNAi is attractive because it enables silencing of cancer targets that cannot be inhibited using conventional approaches. We have several lines of evidence that our lead drug, EFTX- 001, potently silences the majority of missense mutations and spares the WT sequence. Using an FDA-approved lipid nanoparticle (LNP) delivery system, we have already found impressive therapeutic potential for delivering EFTX-001 in lung cancer models with no detectable toxicity. Taken together, key questions arise, such as: 1) Which KRAS missense mutations are most potently targeted by EFTX-001? 2) What toxic effects does LNP- EFTX-001 have on healthy adult tissue (e.g. liver, kidney and bone marrow)? 3) What is the therapeutic index of LNP-EFTX-001 in KRAS-dependent cancer models? We hypothesize that LNP-EFTX-001 will potently silence multiple clinically-relevant KRAS mutations in lung and colon cancers while sparing the wild-type sequence; consequently, inhibiting tumor progression with a highly satisfactory toxicity profile. The objectives of this proposal are: 1) to define how potently EFTX-001 targets the most common KRAS mutations while sparing the WT sequence, 2) to evaluate the effects of EFTX-001 on MAP kinase signaling and cell viability, 3) use in vitro and in vivo models to determine the therapeutic index of silencing mutant versus WT KRAS in cancer and adult tissues, respectively.

研究总结： KRAS原癌基因是癌症中最关键的基因之一，但它也被证明是癌症中最重要的基因之一。 最难以捉摸的几乎所有（98%）的KRAS错义突变都发生在密码子12或13中，这导致组成型突变。 KRAS激活和促进许多癌症标志。尽管激酶抑制剂已经彻底改变了 治疗由其他分子畸变驱动的癌症的一些子集，在突变体中缺乏这种成功， KRAS驱动的癌症导致KRAS本身被广泛认为是“不可治愈的”。虽然有G12 C 目前正在开发的抑制剂，这些疗法仅限于一种KRAS突变，仅占 约12%的KRAS突变，因此治疗范围有限。我们成立了C公司， EnFuego Therapeutics，Inc.通过使用RNA来解决癌症中越来越多的“不可治疗”的靶点， 干扰（RNAi）为基础的治疗。RNAi是有吸引力的，因为它能够沉默癌症靶点， 不能使用常规方法抑制。我们有几条证据证明我们的主要药物，EFTX- 001，有效地沉默了大多数错义突变并保留了WT序列。使用FDA批准的 脂质纳米粒（LNP）递送系统，我们已经发现了令人印象深刻的治疗潜力， EFTX-001在肺癌模型中未检测到毒性。综上所述，出现了一些关键问题，例如：1） EFTX-001最有效靶向哪些KRAS错义突变？2)LNP有什么毒性作用- EFTX-001对健康成人组织（例如肝脏、肾脏和骨髓）的影响？3)治疗指数是多少 LNP-EFTX-001在KRAS依赖性癌症模型中的作用？我们假设LNP-EFTX-001将有效沉默 肺癌和结肠癌中的多种临床相关KRAS突变，同时保留野生型序列; 从而抑制肿瘤进展，具有非常令人满意的毒性特征。这一目标 建议：1）定义EFTX-001靶向最常见KRAS突变的有效性，同时保留 WT序列，2）评价EFTX-001对MAP激酶信号传导和细胞活力的影响，3）体外使用 和体内模型，以确定癌症和成人中沉默突变体相对于WT KRAS的治疗指数 组织，分别。